ClinicalTrials.gg
RecruitingNCT07670416Updated Nov 5, 2026

A Study to Evaluate the Effects of Enicepatide in Participants With Obesity or Overweight, With or Without Type 2 Diabetes

A Phase 3 interventional study of Enicepatide and Placebo in Obesity, Overweight and Type 2 Diabetes Mellitus (T2DM), sponsored by Hoffmann-La Roche. Recruiting at 21 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies in Obesity by Hoffmann-La Roche — 8 open to participants now, 12 under way, 7 of them phase 3. Obesity · Hoffmann-La Roche.

Planned enrollment
11th of 21
300 · median 300
Started
2026
with 7 others
Phase 3
8 of 21
7 open now
Primary completion
2028-02
later than 5 of 11 live
Registered
17th of 21
by date

Among the 21 studies in Obesity by Hoffmann-La Roche, this one is the 11th largest by planned enrollment, is one of 8 that started in 2026, is one of 8 in phase 3, reaches primary completion later than 5 of the 11 other live ones, and was the 17th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

8 of the 21 studies in Obesity by Hoffmann-La Roche are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Obesity by Hoffmann-La Roche, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of enicepatide, a dual glucagon-like peptide-1 (GLP-1)/glucose-dependent insulinotropic polypeptide (GIP) receptor agonist (RA) being developed for chronic weight management, as an adjunct to a reduced-calorie diet and increased physical activity in participants without Type 2 diabetes mellitus (T2DM) who have obesity or overweight with at least one weight-related comorbidity, and in participants with T2DM who have obesity or overweight.

03

Conditions studied

  • Obesity
  • Overweight
  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) ≥24.0 kilograms per meter squared (kg/m\^2) for participants with type 2 diabetes mellitus (T2DM)
  • BMI ≥28.0 kg/m\^2 or BMI ≥24.0 and \<28.0 kg/m\^2 and diagnosed with at least one weight-related comorbidity (prediabetes, hypertension, dyslipidemia, fatty liver, obstructive sleep apnea, or weight-related cardiovascular disease) for participants without T2DM
  • Agreement to adhere to the requirements

Exclusion criteria

Exclusion Criteria:

  • History of Type 1 diabetes mellitus (T1DM)
  • Obesity induced by other endocrinologic disorders
  • Any planned major medical procedure or surgery during the study
  • History of significant active or unstable major depressive disorder (MDD) or other severe psychiatric disorder
  • Any lifetime history of suicide attempt
  • History of any hematologic conditions that may interfere with measurement
  • History of acute or chronic pancreatitis or clinically significant gallbladder disease
  • Treatment with any approved or GLP-1-RA-based therapy within 6 months prior to randomization
  • Treatment with other investigational therapy within 3 months prior to randomization or less than 5 elimination half-lives prior to randomization, whichever is longer
  • Known allergy to any component of the study drug formulation or any other condition that is a to GLP-1 RAs or GLP-1/GIP RAs
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Enicepatide Dose 1

    Participants will receive enicepatide Dose 1.

    Combination Product: Enicepatide

  • Experimental
    Enicepatide Dose 2

    Participants will receive enicepatide Dose 2.

    Combination Product: Enicepatide

  • Experimental
    Enicepatide Dose 3

    Participants will receive enicepatide Dose 3.

    Combination Product: Enicepatide

  • Placebo comparator
    Placebo

    Participants will receive matching placebo.

    Combination Product: Placebo

Interventions

  • Combination productEnicepatide

    Participants will receive enicepatide via subcutaneous (SC) injection as per the schedule in the protocol.

    Also known as: RO7795068, CT-388, RG6640

  • Combination productPlacebo

    Participants will receive matching placebo via SC injection as per the schedule in the protocol.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 52

    Time frame: Baseline through Week 52

Secondary outcomes

  1. Percentage of Participants Achieving ≥5% Body Weight Loss at Week 52

    Time frame: At Week 52

  2. Percentage of Participants Achieving ≥10% Body Weight Loss at Week 52

    Time frame: At Week 52

  3. Percentage of Participants Achieving ≥15% Body Weight Loss at Week 52

    Time frame: At Week 52

  4. Percentage of Participants Achieving ≥20% Body Weight Loss, in Participants Receiving Enicepatide Dose 2 and Dose 3

    Time frame: At Week 52

  5. Change From Baseline in Body Weight at Week 52

    Time frame: Baseline through Week 52

  6. Change From Baseline in Waist Circumference at Week 52

    Time frame: Baseline through Week 52

  7. Change From Baseline in Fasting Glucose at Week 52

    Time frame: Baseline through Week 52

  8. Change From Baseline in Fasting Insulin at Week 52

    Time frame: Baseline through Week 52

  9. Change From Baseline in Low-Density Lipoprotein (LDL) Cholesterol at Week 52

    Time frame: Baseline through Week 52

  10. Change From Baseline in High-Density Lipoprotein (HDL) Cholesterol at Week 52

    Time frame: Baseline through Week 52

  11. Change From Baseline in Triglyceride at Week 52

    Time frame: Baseline through Week 52

  12. Change From Baseline in Systolic Blood Pressure at Week 52

    Time frame: Baseline through Week 52

  13. Change From Baseline in the Physical Functioning as Assessed by Short Form 36 Health Survey Acute, Version 2.0 (SF-36 v2 Acute) at Week 52

    Time frame: Baseline through Week 52

  14. Change From Baseline in Physical Functioning Composite Score as Assessed by Impact of Weight on Quality of Life-Lite Clinical Trials Version (IWQoL-Lite-CT) Questionnaire at Week 52

    Time frame: Baseline through Week 52

  15. Percent Change From Baseline in Body Weight at Week 52 in GLP-1 RA-based Treatment Naive Populations

    Time frame: Baseline through Week 52

  16. Change From Baseline in Waist-to-Hip Ratio at Week 52

    Time frame: Baseline through Week 52

  17. Change From Baseline in Waist-to-Height Ratio at Week 52

    Time frame: Baseline through Week 52

  18. Percentage of Participants With Prediabetes at Baseline Achieving Normoglycemia (Hemoglobin A1c [HbA1c] <5.7%) at Week 52

    Time frame: At Week 52

  19. Change From Baseline in Health Related Quality of Life (HRQoL) as Assessed by the SF-36v2 Acute Domain Scores and Component Summary Scores at Week 52

    Time frame: Baseline through Week 52

  20. Change From Baseline in HRQoL as Assessed by the IWQoL-Lite-CT Questionnaire Domain Scores and Total Score at Week 52

    Time frame: Baseline through Week 52

  21. Change From Baseline in Non-HDL Cholesterol at Week 52

    Time frame: Baseline through Week 52

  22. Change From Baseline in Very Low Density Lipoprotein (VLDL) Cholesterol at Week 52

    Time frame: Baseline through Week 52

  23. Change From Baseline in Total Cholesterol at Week 52

    Time frame: Baseline through Week 52

  24. Change From Baseline in Free Fatty Acids at Week 52

    Time frame: Baseline through Week 52

  25. Change From Baseline in Diastolic Blood Pressure at Week 52

    Time frame: Baseline through Week 52

  26. Change From Baseline in High-Sensitivity C-Reactive Protein (hsCRP) at Week 52

    Time frame: Baseline through Week 52

  27. Change From Baseline in Serum Uric Acid at Week 52

    Time frame: Baseline through Week 52

  28. Percentage of Participants Achieving ≥25% Body Weight Loss at Week 52, in Participants Receiving Enicepatide Dose 2 and Dose 3

    Time frame: Baseline through Week 52

  29. Change From Baseline in Body Mass Index (BMI) at Week 52

    Time frame: Baseline through Week 52

  30. Percent Change From Baseline in Body Weight by Obesity Class at Week 52

    Time frame: Baseline through Week 52

  31. Change From Baseline in HbA1c at Week 52 in Participants With T2DM

    Time frame: Baseline through Week 52

  32. Percentage of Participants With T2DM Achieving HbA1c of <5.7%, ≤6.5% and <7% at Week 52

    Time frame: At Week 52

  33. Change From Baseline in Total Lean Tissue Volume at Week 52

    Time frame: Baseline through Week 52

  34. Percent Change From Baseline in Total Lean Tissue Volume at Week 52

    Time frame: Baseline through Week 52

  35. Change From Baseline in Total Adipose Tissue Volume at Week 52

    Time frame: Baseline through Week 52

  36. Percent Change From Baseline in Total Adipose Tissue Volume at Week 52

    Time frame: Baseline through Week 52

  37. Incidence and Severity of Adverse Events, With Severity Determined According to Mild, Moderate, and Severe Criteria

    Time frame: Baseline to Safety Follow-Up (55 Weeks)

  38. Change From Baseline in the Columbia-Suicide Severity Rating Scale (C-SSRS) Score

    Time frame: Baseline through Week 52

  39. Change From Baseline in the Patient Health Questionnaire-9 (PHQ-9) Score

    Time frame: Baseline through Week 52

07

Study locations

21 of 21 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Feb 2028, 19 months after the start.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's planned 19 months is close to that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 22, 2026
First posted
Jun 26, 2026
StartActual
Jul 3, 2026
Primary completionEst.
Feb 24, 2028
CompletionEst.
Mar 15, 2028
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
2 updates, last Nov 5, 2026
Show all 2 updates
  1. Nov 5, 2026
    Minor edits only
    + 1 other change: verification date
  2. Oct 8, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07670416
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 26, 2026
Start date
Jul 3, 2026
Primary completion
Feb 24, 2028 (estimated)
Completion
Mar 15, 2028 (estimated)
Last update
Nov 5, 2026

Study contacts

Reference Study ID Number: YC46401 https://forpatients.roche.com No attachments to email below.
Contact
global-roche-genentech-trials@gene.com
888-662-6728 (U.S. Only)
Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Contact
Clinical Trials
study director · Hoffmann-La Roche

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enicepatide

Start the discussion